Idexx Laboratories (IDXX)
NASDAQ:IDXX
Want to see IDXX full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
3.95Last Year’s EPS
3.63Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong top-line growth, robust recurring revenue and instrument placement momentum, margin expansion, healthy EPS and cash generation, and continued adoption of new diagnostic innovations (inVue Dx, Cancer DX) and software solutions. These positives substantially outweigh the headwinds disclosed: modest declines in clinical visits (especially wellness), flat rapid assay revenues due to platform migration, some supply-chain impacts in Water, and a few discrete expense items (equity loss, prior litigation). Management raised full-year guidance and reaffirmed growth drivers while acknowledging macro and FX sensitivities. Overall, the tone is confident and constructive with execution-focused follow-through on innovation rollouts and international expansion.Company Guidance
Revenue Growth (Q1 and Updated FY Outlook)
Reported revenue increased 14% year-over-year in Q1; organic revenue grew 11%. Management raised full-year 2026 revenue guidance to $4.675B–$4.76B (roughly 8.6%–10.6% reported growth), an increase of ~$42M at midpoint versus prior guidance and ~70 bps uplift to organic growth at midpoint.
CAG Diagnostics Recurring Revenue Momentum
CAG Diagnostics recurring revenue grew ~11% organically in Q1 (U.S. nearly 11%, international ~12%). Full-year organic CAG Diagnostic recurring revenue outlook updated to 8.7%–10.7%, supported by ~4% net price realization and continued volume/usage gains.
Premium Instrument Placements and Installed Base Expansion
CAG instrument revenue grew 28% organically in Q1, with 1,100 IDEXX inVue Dx instruments placed during the quarter. Premium instrument placements totaled 4,650 units in the quarter (12% YoY), and the company is tracking to a full-year target of 5,500 inVue Dx placements, with installed base up ~12% YoY.
Profitability and EPS
Comparable operating margin expanded by ~100 basis points in Q1; gross margin was 63.4%, up ~90 bps on a comparable basis. Comparable operating profit rose 15% and comparable EPS increased 15% to $3.47 in Q1. Full-year EPS guidance raised to $14.45–$14.90 (up $0.13 at midpoint).
Recurring Revenue and Consumables Strength
IDEXX VetLab consumables organic revenue grew 15% in Q1 driven by double-digit volume expansion in the U.S. and internationally tied to premium instrument installed base growth and increased utilization. Vet software and imaging recurring revenues grew 11% organically.
Reference Lab and Diagnostic Innovation Adoption
Global Reference Lab revenues increased 10% organically in Q1 with contributions from net new customers and higher same-store utilization. Cancer DX adoption continues to build: >7,500 practices have ordered since launch and ~70% of North America tests run as part of panels; Cancer DX launched internationally in Europe and Australia in Q1.
Record Imaging Placements and Software Momentum
Diagnostic imaging set a quarterly record with ~330 installations (DR50 PLUS launch), cloud-native PIMS installations grew double digits, and pet-owner engagement app Vello grew double digits quarter-over-quarter.
Cash Generation and Capital Allocation
Free cash flow was $234M in Q1; trailing 12-month net income to free cash flow conversion reached 99%. Full-year free cash flow conversion target maintained at 85%–95% of net income. IDEXX repurchased $361M of stock in Q1, reducing diluted shares ~2.1% YoY.
Financial Position and Leverage
Leverage remained low with 0.6x gross and 0.5x net of cash. Foreign exchange contributed ~$14M to operating profit and ~$0.14 to EPS in Q1 (net of hedges).
Product Rollouts and Long-Term Opportunity
Controlled rollout of inVue Dx F&A is on track with positive early feedback; management highlighted a multi-product roadmap (inVue Dx menu expansion, Cancer DX additions, AI capabilities) and continued commercial investment internationally as drivers of long-term growth.
IDXX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IDXX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $563.12 | $562.97 | -0.03% |
Feb 02, 2026 | $670.46 | $639.60 | -4.60% |
Nov 03, 2025 | $629.51 | $722.94 | +14.84% |
Aug 04, 2025 | $535.54 | $682.78 | +27.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Idexx Laboratories (IDXX) report earnings?
Idexx Laboratories (IDXX) is schdueled to report earning on Aug 04, 2026, Before Open (Confirmed).
What is Idexx Laboratories (IDXX) earnings time?
Idexx Laboratories (IDXX) earnings time is at Aug 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IDXX EPS forecast?
IDXX EPS forecast for the fiscal quarter 2026 (Q2) is 3.95.